New Jersey Pharma Co. Shares Positive Pediatric Study
Source: Dr. Ram Selvaraju  (4/2/25)
Aquestive Therapeutics Inc. (AQST:NASDAQ) recently reported that it completed New Drug Application (NDA) submission for Anaphylm and positive pediatric study data for the non-device-based epinephrine product candidate, noted an H.C. Wainwright & Co. research note. More >

Clean Tech Co. Achieves Record-Breaking Revenue for Exceptional Growth
Source: Streetwise Reports  (4/1/25)
BioLargo Inc. (BLGO:OTCQX) announced in its annual report that in 2024 it saw record revenues and an increase of 45% over the year before. Read why an expert and an analyst both like this clean technology company's story. More >

GMP Production of Exosomes Slated for Later This Year
Source: Jason Kolbert  (3/31/25)
This is a next big step for the biotech in moving its investigational exosome therapy for chronic inflammation into the clinic, noted a D. Boral Capital report. More >

Biotech Co. Advances AI-Generated Cancer Treatments
Source: Streetwise Reports  (3/28/25)
Rakovina Therapeutics Inc. (RKV:TSX.V) receives the first synthesized batch of artificial intelligence-generated ATR inhibitor compounds developed in collaboration with Variational AI. Find out why the technology could revolutionize the way we treat cancer. More >

Biotech Advances Revolutionary Treatment for Neurodegenerative Diseases
Source: Streetwise Reports  (3/28/25)
Clinical-stage biotechnology company Coya Therapeutics Inc.'s (COYA:NASDAQ) regulatory T cell-derived exosome (Treg exosome) program is set to enter Good Manufacturing Production (GMP) late this year, paving the way for an initial clinical study. Find out why one analyst calls the company's work a "potential breakthrough." More >

Chen Highlights His Premium Silver, Gold Opportunities for Q2
Source: Streetwise Reports  (3/25/25)
Even with tariff chaos, asset manager Chen Lin of What is Chen Buying? What is Chen Selling? said he is still bullish in the near term for gold silver. Find out which stocks are his top picks for the coming quarter. More >

PDUFA Date Nearing for New PSVT Drug
Source: Patrick Trucchio  (3/19/25)
If approved, commercialization will start mid-year; the biopharma behind the treatment offers a potential return of 1,052%, noted an H.C. Wainwright & Co. report. More >

Two Use Cases for AI in Healthcare
Source: Streetwise Reports  (3/14/25)
In both, proprietary software platforms analyze heaps of data, but one focuses on genetics, the other neurology. Learn more about the companies behind the technology. More >

US$200M Deal Accelerates Phase 3 Gene Therapy for Parkinsons
Source: Streetwise Reports  (3/14/25)
MeiraGTx Holdings Plc.'s (MGTX:NASDAQ) partnership with Hologen AI secures US$200 million to advance its Phase 3 gene therapy for Parkinson's. With regulatory milestones ahead, here's what's next.

More >

Biotech Stock Looks Like Is Has a Great Set Up
Source: Clive Maund  (3/12/25)
Technical Analyst Clive Maund explains why he thinks Hemostemix Inc. (HEM:TSXV; HMTXF:OTCQB; 2VF0:FSE) is an Immediate Strong Buy. More >

Utah Biotech's Treatment Demonstrates Significant Survival Advantage for ALS Patients
Source: Jason Kolbert  (3/12/25)
Utah biotech Clene Inc. (CLNN:NASDAQ) recently shared new data, reporting the survival benefit of its CNM-Au8 treatment for ALS patients, according to a D. Boral Capital research note. More >

AI Study Tracks Unexpected Cognitive Gains in Vascular Dementia Trial
Source: Streetwise Reports  (3/11/25)
Hemostemix Inc.'s (HEM:TSXV; HMTXF:OTCQB; 2VF0:FSE) Phase 1 trial, in collaboration with Firefly Neuroscience Inc. (AIFF:NASDAQ), is evaluating ACP-01s impact on vascular dementia using AI-driven brain analysis. Early insights could reshape treatment approaches. More >

Biotech Advancing Pivotal Phase III Breast Cancer Trial
Source: Dr. Douglas Loe  (3/11/25)
Oncolytics Biotech Inc. (ONCY:NASDAQ; ONC:TSX) recently updated its timelines for the company's clinical testing, regulatory review, and potential commercial launch of its oncolytic reovirus formulation pelareorep in breast cancer, according to a report from Leede Financial Inc. More >

FDA OKs Trial of Cell Reservoir in Thyroid Disease
Source: Dr. Douglas Loe  (3/10/25)
In this Phase 1 study, post-thyroidectomy patients will be treated with their own thyroid cells via this implantable delivery device, noted a Leede Financial Inc. report. More >

With Competitor Out, New Drug Gains Edge in Chronic Cough
Source: Jason Kolbert  (3/10/25)
Phase 2b data, expected in H1/25, could support advancement of the therapeutic into late-stage development, noted a D. Boral Capital report. More >

New Drug for Major Depressive Disorder Gets Good Surprise
Source: Douglas Tsao  (3/10/25)
When a key competitor drops out, this treatment moves to top runner position; the biopharma behind it offers 1,084% upside, noted an H.C. Wainwright & Co. report. More >

Biotech Hits Critical Milestone for Cell-Pouch Bio-Hybrid Organ
Source: Streetwise Reports  (3/6/25)
Sernova Biotherapeutics Inc. (SVA:TSX.V; SEOVF:OTCQB; PSH:XETRA) announces that the FDA has cleared its investigational new drug (IND) application for its cell pouch with auto-transplanted thyroid cells in patients undergoing thyroid surgery for nodular thyroid disease. Find out why one analyst sees big returns coming from the stock. More >

Canadian Healthcare Co. Showcases Stable FQ424
Source: Dr. Douglas Loe  (3/6/25)
Leede Financial Inc. raised its target price on CareRX Corp. (CRRX:TSX; CHHHF:OTCMKTS). Read on to see why one Leede analyst rates the stock as a Buy. More >

Breakthrough ADHD Treatment Moves Closer to FDA Approval with New Data
Source: Streetwise Reports  (3/5/25)
Cingulate Inc.'s (CING:NASDAQ), latest Phase 3 data reinforces CTx-1301s potential as a true once-daily ADHD treatment. With an FDA meeting on the horizon, all eyes are on what's next. More >

Virtual Healthcare Breakthrough Expanding Access for 6.9M Medicaid Patients in New York
Source: Streetwise Reports  (2/27/25)
Rocket Doctor, under Treatment.com AI Inc. (TRUE:CSE; TREIF:OTCMKTS; 939:FRA), is now an in-network provider for New York Medicaid, expanding virtual healthcare access to 6.9 million beneficiaries. Find out how this milestone offers the possibility to reshape healthcare accessibility.

More >

DMT Study Set To Explore Breakthrough Potential in Stroke Recovery
Source: Streetwise Reports  (2/14/25)
Algernon Pharmaceuticals Inc. (AGN:CSE; AGNPF:OTCQB; AGW0:XFRA) subsidiary Algernon NeuroScience has appointed Dr. Sandor Nardai as Principal Investigator for its upcoming Phase 2a DMT stroke study. Find out how this trial could reshape stroke recovery research.

More >

Healthcare Tech Co. To Acquire Digital Health Platform
  (2/13/25)
This will expand its ecosystem of AI-powered products. Read on to learn more about its offerings and rapidly growing sector. More >

New Strategic Moves Aim To Accelerate Growth in AI Healthcare
Source: Streetwise Reports  (2/12/25)
Light AI Inc. (ALGO:CBOE) announces major marketing campaigns, advisory board appointments, and a key regulatory partnership to drive growth. Discover how these strategic moves could shape the future of AI healthcare.

More >

Kentucky Medical Co. Has Strong Operating Fundamentals
Source: Douglas Loe  (2/12/25)
Quipt Home Medical Corp. (QIPT:NASDAQ; QIPT:TSX.V) received a lowered price target but a Buy rating from a Leede Financial Inc. research note. More >

AI Stock in an Uptrend That Is Likely To Continue
Source: Clive Maund  (2/10/25)
Technical Analyst Clive Maund explains why he thinks Light AI Inc. (ALGO:CBOE) is an Immediate Strong Buy. More >